Tilray Brands Stock Earnings Reports

Tilray reported a strong Q2 FY2026 with record net revenue of ~$218M and improved profitability and liquidity. Key financials: adjusted EBITDA of $8.4M, adjusted cash operating income of $6M, GAAP net loss narrowed to $43.5M (49% YoY improvement), operating cash use fell to $8.5M, and cash & marketable securities of $291.6M resulting in a net cash position of ~ $30M. Business highlights: international cannabis drove the quarter (cannabis revenue $67.5M; international cannabis +36% YoY and +51% sequential), distribution revenue grew 26% to $85.3M, beverage revenue was $50.1M but remains under pressure while Project 420 targets $33M in annualized savings, and wellness was stable at $14.6M. Strategic/operational points: Tilray emphasizes its global footprint (40+ brands, 20+ countries), Tilray Medical run-rate near $150M, expanded cultivation capacity (~200 metric tons annual after Cayuga harvest), and significant European scale (Germany, U.K., Poland, etc.). Management is positioning the company to capitalize on U.S. federal rescheduling (Schedule III) — expecting to leverage medical/regulatory experience, clinical programs, genetics and distribution to scale quickly. Guidance and priorities: management reaffirmed FY2026 adjusted EBITDA guidance of $62M–$72M, will continue to redeploy supply toward higher-margin international markets, and plans further balance-sheet strengthening. Risks/considerations for investors: continued price compression in some cannabis categories (notably flower), permit/regulatory timing in Europe (Portugal/Germany), craft-beer/beverage segment headwinds and longer integration/turnaround timeline, and potential regulatory uncertainty for hemp-derived intoxicating products after 2026.